ПОИСК МЕТАБОЛОМНЫХ ПРЕДИКТОРОВ СЕРДЕЧНО-СОСУДИСТЫХ ОСЛОЖНЕНИЙ У ПАЦИЕНТОВ С ВПЕРВЫЕ ВЫЯВЛЕННЫМ НЕМЕЛКОКЛЕТОЧНЫМ РАКОМ ЛЕГКОГО (ОБЗОР)

УДК 616.24-006.6:616.1-071

Авторы

  • Темирлан Серикович Зарханов Новосибирский национальный исследовательский государственный университет, г. Новосибирск Email: lozhkina.n@mail.ru
  • Наталья Геннадьевна Ложкина Новосибирский национальный исследовательский государственный университет, г. Новосибирск; Федеральный исследовательский центр фундаментальной и трансляционной медицины, г. Новосибирск https://orcid.org/0000-0002-4832-3197 Email: lozhkina.n@mail.ru

DOI:

https://doi.org/10.31684/25418475-2024-1-128

Ключевые слова:

рак легкого, сердечно-сосудистые заболевания, немелкоклеточный рак легкого, метаболомное исследование

Аннотация

Рак легкого является наиболее распространенным злокачественным новообразованием в мире. Чаще всего этому заболеванию подвержены пожилые люди и курильщики, имеющие сопутствующие сердечно-сосудистые заболевания. Коморбидность может влиять на прогноз, а также осложнять лечение. Таким образом, необходимо разработать и внедрить новые инструменты для диагностики, прогнозирования и персонализации лечения данной категории пациентов. Использованы сведения по теме из публикаций на основе баз данных PubMed, Google Scholar и E-library.

Скачивания

Данные скачивания пока недоступны.

Информация об авторах

Темирлан Серикович Зарханов,
Новосибирский национальный исследовательский государственный университет, г. Новосибирск

студент 6-го курса института медицины и психологии им. Зельмана, Новосибирский национальный исследовательский государственный университет, г. Новосибирск.
E-mail: lozhkina.n@mail.ru.

Наталья Геннадьевна Ложкина,
Новосибирский национальный исследовательский государственный университет, г. Новосибирск; Федеральный исследовательский центр фундаментальной и трансляционной медицины, г. Новосибирск

д. м. н., профессор, руководитель группы «Клиническая и экспериментальная кардиология», ФИЦ ФТМ; профессор кафедры иммунологии, Новосибирский национальный исследовательский государственный университет; кардиолог, куратор отделения для лечения больных с острым коронарным синдромом РСЦ № 1 ГКБ № 1, г. Новосибирск.
E-mail: lozhkina.n@mail.ru.
https://orcid.org/0000-0002-4832-3197.

Библиографические ссылки

  • Haznadar M. et al. Urinary metabolite risk biomarkers of lung cancer: A prospective cohort study. Cancer Epidemiology Biomarkers and Prevention. American Association for Cancer Research Inc. 2016; 25(6): 978-986. https://doi.org/10.1158/1055-9965.EPI-15-1191
  • American Cancer Society. Global cancer facts & figures. 4th edition. Atlanta, GA: American Cancer Society. 2018.
  • Bray F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. Wiley. 2018; 68(6): 394-424. https://doi.org/10.3322/caac.21492
  • Федеральная служба государственной статистики (Росстат). Здравоохранение в России 2019: статистический сборник [Интернет]. Москва, 2019: 170.
  • Фаттахов Т.А., Миронова А.А., Пьянкова А.И., Шахзадова А.О. Смертность от новообразований в России в 1965-2019: основные структурные изменения и тенденции. Сибирский онкологический журнал. 2021; 20(4): 5-20. https://doi.org/10.21294/1814-4861-2021-20-4-5-20
  • Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Москва, 2020: 252.
  • American Cancer Society. Cancer facts & figures 2019. Atlanta, GA: American Cancer Society; 2019.
  • Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin. Wiley. 2019; 69(1): 7-34. https://doi.org/10.3322/caac.21551
  • Postmus P.E. et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. Oxford University Press. 2017; 28: iv1-iv21. https://doi.org/10.1093/annonc/mdx222
  • Koene R.J. et al. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016; 133(11). https://doi.org/10.1161/CIRCULATIONAHA.115.020406
  • Mehta L.S. et al. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation. 2018; 137(8). https://doi.org/10.1161/CIR.0000000000000556
  • Al-Kindi S.G., Oliveira G.H. Prevalence of Preexisting Cardiovascular Disease in Patients with Different Types of Cancer the Unmet Need for Onco-Cardiology. Mayo Clin Proc. 2016; 91(1). https://doi.org/10.1016/j.mayocp.2015.09.009
  • Islam K.M.M. et al. Comorbidity and survival in lung cancer patients. Cancer Epidemiology Biomarkers and Prevention. 2015; 24(7). https://doi.org/10.1158/1055-9965.EPI-15-0036
  • Iachina M. et al. The Effect of Different Comorbidities on Survival of Non-small Cells Lung Cancer Patients. Lung. 2015; 193(2). https://doi.org/10.1007/s00408-014-9675-5
  • Rami-Porta R. et al. The IASLC lung cancer staging project: The new database to inform the eighth edition of the TNM classification of lung cancer. Journal of Thoracic Oncology. Elsevier Inc. 2014; 9(11): 1618-1624. https://doi.org/10.1097/JTO.0000000000000334
  • Chansky K. et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology. Elsevier Inc. 2017; 12(7): 1109-1121.
  • Wahbah M. et al. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol. 2007; 11(2): 89-96. https://doi.org/10.1016/j.anndiagpath.2006.04.006
  • Pao W., Girard N. Review New driver mutations in non-small-cell lung cancer. 2011. https://doi.org/10.1016/S1470-2045(10)70087-5
  • Hirsch F.R. et al. Lung cancer: current therapies and new targeted treatments. The Lancet. Lancet Publishing Group. 2017; 389(10066): 299-311. https://doi.org/10.1016/S0140-6736(16)30958-8
  • Zhu Q.-G. et al. Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. 2017; 8(34): 57680-57692. https://doi.org/10.18632/oncotarget.17016
  • Jones A., Gulbis A., Baker E.H. Differences in tobacco use between Canada and the United States. International Journal of Public Health. 2010; 55(3). https://doi.org/10.1007/s00038-009-0101-3
  • Erratum: Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016 (The Lancet (2017) 390(10100) (1151-1210) (S0140673617321529) (10.1016/S0140-6736(17)32152-9)). The Lancet. 2017; 390: 10106.
  • Dawber T.R. et al. Some factors associated with the development of coronary heart disease: six years’ follow-up experience in the Framingham study. Am J Public Health. 1959; 49. https://doi.org/10.2105/AJPH.49.10.1349
  • Masoudkabir F. et al. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017; 263. https://doi.org/10.1016/j.atherosclerosis.2017.06.001
  • Ligibel J.A. et al. American Society of Clinical Oncology position statement on obesity and cancer. Journal of Clinical Oncology. 2014; 32(31). https://doi.org/10.1200/JCO.2014.58.4680
  • Tourmousoglou C.E., Apostolakis E., Dougenis D. Simultaneous occurrence of coronary artery disease and lung cancer: what is the best surgical treatment strategy? Interactive cardiovascular and thoracic surgery. 2014; 19(4). https://doi.org/10.1093/icvts/ivu218
  • Kreatsoulas C., Anand S.S., Subramanian S. V. An emerging double burden of disease: The prevalence of individuals with cardiovascular disease and cancer. J Intern Med. 2014; 275(5). https://doi.org/10.1111/joim.12165
  • Inohara T., Endo A., Melloni C. Unmet Needs in Managing Myocardial Infarction in Patients With Malignancy. Frontiers in Cardiovascular Medicine. 2019; 6. https://doi.org/10.3389/fcvm.2019.00057
  • Hayat M.J. et al. Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007; 12(1). https://doi.org/10.1634/theoncologist.12-1-20
  • Little A.G. et al. National survey of non-small cell lung cancer in the United States: Epidemiology, pathology and patterns of care. Lung Cancer. 2007; 57(3). https://doi.org/10.1016/j.lungcan.2007.03.012
  • Extermann M. Interaction between comorbidity and cancer. Cancer Control. 2007; 14(1). https://doi.org/10.1177/107327480701400103
  • Battafarano R.J. et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 2002; 123(2). https://doi.org/10.1067/mtc.2002.119338
  • Janssen-Heijnen M.L.G. et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: A population-based study. Lung Cancer. 1998; 21(2). https://doi.org/10.1016/S0169-5002(98)00039-7
  • Ambrogi V. et al. The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer. European Journal of Cardio-thoracic Surgery. 2003; 23(5). https://doi.org/10.1016/S1010-7940(03)00093-9
  • Kocher F. et al. Cardiovascular comorbidities and events in NSCLC: Often underestimated but worth considering. Clin Lung Cancer. 2015; 16(4). https://doi.org/10.1016/j.cllc.2014.12.007
  • Kravchenko J. et al. Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis. Lung Cancer. 2015; 88(1). https://doi.org/10.1016/j.lungcan.2015.01.006
  • Pater J.L., Loeb M. Nonanatomic prognostic factors in carcinoma of the lung. A multivariate analysis. Cancer. 1982; 50(2). https://doi.org/10.1002/1097-0142(19820715)50:2%3C326::AID-CNCR2820500227%3E3.0.CO;2-G
  • Piccirillo J.F., Feinstein A.R. Clinical symptoms and comorbidity: Significance for the prognostic classification of cancer. Cancer. 1996; 77(5). https://doi.org/10.1002/(SICI)1097-0142(19960301)77:5%3C834::AID-CNCR5%3E3.3.CO;2-Z
  • Beauchamp G L.J.S. articles by ’Lassonde J.L.J.L.F.L.A. Lung cancer and peripheral vascular surgery.
  • Duque J.L. et al. Early complications in surgical treatment of lung cancer: A prospective, multicenter study. Annals of Thoracic Surgery. 1997; 63(4). https://doi.org/10.1016/S0003-4975(97)00051-9
  • Voets A.J., Joesoef K.S., Van Teeffelen M.E.J.M. Synchroneously occurring lung cancer (stages I-II) and coronary artery disease: Concomitant versus staged surgical approach. European Journal of Cardio-thoracic Surgery. 1997; 12(5). https://doi.org/10.1016/S1010-7940(97)00240-6
  • Batra A. et al. Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer. BMC Cancer. 2020; 20(1). https://doi.org/10.1186/s12885-020-07487-9
  • Tseng C.C. et al. Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention. Tumor Biology. Springer Science and Business Media B.V. 2016; 37(9): 11873-11882. https://doi.org/10.1007/s13277-016-5047-5
  • Pirozynski M. 100 years of lung cancer. Respiratory Medicine. W.B. Saunders Ltd. 2006; 100(12): 2073-2084. https://doi.org/10.1016/j.rmed.2006.09.002
  • Khakimov B. et al. From metabolome to phenotype: GC-MS metabolomics of developing mutant barley seeds reveals effects of growth, temperature and genotype. Sci Rep. Nature Publishing Group. 2017; 7(1). https://doi.org/10.1038/s41598-017-08129-0
  • Robles A.I., Harris C.C. Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer. Lung Cancer. 2017; 107. https://doi.org/10.1016/j.lungcan.2016.06.003
  • Tumas J. et al. Metabolomics in pancreatic cancer biomarkers research. Medical Oncology. 2016; 33(12). https://doi.org/10.1007/s12032-016-0853-6
  • Nagana Gowda G.A. et al. Visualization of bile homeostasis using 1H-NMR spectroscopy as a route for assessing liver cancer. Lipids. 2009; 44(1). https://doi.org/10.1007/s11745-008-3254-6
  • Claudino W.M. et al. Metabolomics: Available results, current research projects in breast cancer, and future applications. Journal of Clinical Oncology. 2007; 25(19). https://doi.org/10.1200/JCO.2006.09.7550
  • DeFeo E.M. et al. A decade in prostate cancer: From NMR to metabolomics. Nature Reviews Urology. 2011; 8(6). https://doi.org/10.1038/nrurol.2011.53
  • Fan T.W.M. et al. Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009; 8. https://doi.org/10.1186/1476-4598-8-41
  • Deja S. et al. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. J Pharm Biomed Anal. 2014; 100. https://doi.org/10.1016/j.jpba.2014.08.020
  • Calderón-Santiago M. et al. Human sweat metabolomics for lung cancer screening. Anal Bioanal Chem. 2015; 407(18). https://doi.org/10.1007/s00216-015-8700-8
  • Cameron S.J.S. et al. The metabolomic detection of lung cancer biomarkers in sputum. Lung Cancer. 2016; 94. https://doi.org/10.1016/j.lungcan.2016.02.006
  • Gottschalk M. et al. Metabolomic studies of human lung carcinoma cell lines using in vitro 1H NMR of whole cells and cellular extracts. NMR Biomed. 2008; 21(8). https://doi.org/10.1002/nbm.1258
  • Horváth I. et al. Exhaled biomarkers in lung cancer. European Respiratory Journal. 2009; 34(1). https://doi.org/10.1183/09031936.00142508
  • Li Y. et al. Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2014; 966. https://doi.org/10.1016/j.jchromb.2014.04.047
  • Roberts L.D. et al. Targeted metabolomics. Curr Protoc Mol Biol. 2012; 1(SUPPL.98). https://doi.org/10.1002/0471142727.mb3002s98
  • Vrhovsek U. et al. A versatile targeted metabolomics method for the rapid quantification of multiple classes of phenolics in fruits and beverages. Journal of Agricultural and Food Chemistry. 2012; 60(36). https://doi.org/10.1021/jf2051569
  • Cai Y., Zhou Z., Zhu Z.J. Advanced analytical and informatic strategies for metabolite annotation in untargeted metabolomics. TrAC – Trends in Analytical Chemistry. 2023; 158. https://doi.org/10.1016/j.trac.2022.116903
  • Guo Y. et al. Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry. Clinica Chimica Acta. 2012; 414. https://doi.org/10.1016/j.cca.2012.08.010
  • Pamungkas A.D. et al. High resolution metabolomics to discriminate compounds in serum of male lung cancer patients in South Korea. Respir Res. 2016; 17(1). https://doi.org/10.1186/s12931-016-0419-3
  • Strongman H. et al. Does Cardiovascular Mortality Overtake Cancer Mortality During Cancer Survivorship? An English Retrospective Cohort Study. JACC CardioOncol. 2022; 4(1). https://doi.org/10.1016/j.jaccao.2022.01.102
  • Imperatori A. et al. Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study. J Cardiothorac Surg. 2012; 7(1). https://doi.org/10.1186/1749-8090-7-4
  • Onaitis M. et al. Risk factors for atrial fibrillation after lung cancer surgery: Analysis of the society of thoracic surgeons general thoracic surgery database. Annals of Thoracic Surgery. 2010; 90(2). https://doi.org/10.1016/j.athoracsur.2010.03.100
  • Cardinale D. et al. Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial. Ann Surg. 2016; 264(20). https://doi.org/10.1097/SLA.0000000000001626
  • Smilowitz N.R. et al. Perioperative major adverse cardiovascular and cerebrovascular events associated with noncardiac surgery. JAMA Cardiol. 2017; 2(2). https://doi.org/10.1001/jamacardio.2016.4792
  • Darby S.C. et al. Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer. New England Journal of Medicine. 2013; 368(11). https://doi.org/10.1056/NEJMoa1209825
  • Van Nimwegen F.A. et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. Journal of Clinical Oncology. 2016; 34(3). https://doi.org/10.1200/JCO.2015.63.4444
  • Atkins K.M. et al. Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. J Am Coll Cardiol. 2019; 73(23). https://doi.org/10.1016/j.jacc.2019.03.500
  • Dess R.T. et al. Cardiac events after radiation therapy: Combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. Journal of Clinical Oncology. 2017; 35(13). https://doi.org/10.1200/JCO.2016.71.6142
  • Wang K. et al. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: Pooled analysis of dose-escalation trials delivering 70 to 90 Gy. Journal of Clinical Oncology. 2017; 35(13). https://doi.org/10.1200/JCO.2016.70.0229
  • Yegya-Raman N. et al. Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC. Journal of Thoracic Oncology. 2018; 13(10). https://doi.org/10.1016/j.jtho.2018.05.028
  • Stam B. et al. Dose to heart substructures is associated with non-cancer death after SBRT in stage I–II NSCLC patients. Radiotherapy and Oncology. 2017; 123(3). https://doi.org/10.1016/j.radonc.2017.04.017
  • Zaborowska-Szmit M. et al. Cardiovascular complications of systemic therapy in non-small-cell lung cancer. J Clin Med. 2020; 9(5). https://doi.org/10.3390/jcm9051268
  • Moore R.A. et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis. Journal of Clinical Oncology. 2011; 29(25). https://doi.org/10.1200/JCO.2011.35.5669
  • Pande A. et al. Hypertension secondary to anti-angiogenic therapy: Experience with bevacizumab. Anticancer Res. 2007; 27(5B).
  • Sandler A.B., Johnson D.H., Herbst R.S. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clinical Cancer Research. 2004; 10(12 II). https://doi.org/10.1158/1078-0432.CCR-040023
  • Choueiri T.K. et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. Journal of Clinical Oncology. 2011; 29(6). https://doi.org/10.1200/JCO.2010.31.9129
  • Scappaticci F.A. et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007; 99(16). https://doi.org/10.1093/jnci/djm086
  • Rao V.U. et al. Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2021; 77(21). https://doi.org/10.1016/j.jacc.2021.04.009
  • Anand K. et al. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). JACC CardioOncol. 2019; 1(2).
  • Tartarone A. et al. Crizotinib-induced cardiotoxicity: The importance of a proactive monitoring and management. Future Oncology. 2015; 11(14). https://doi.org/10.2217/fon.15.47
  • Morcos P.N. et al. Effect of alectinib on cardiac electrophysiology: Results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies. Cancer Chemother Pharmacol. 2017; 79(3). https://doi.org/10.1007/s00280-017-3253-5
  • Gettinger S.N. et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(12). https://doi.org/10.1016/S1470-2045(16)30392-8
  • Escudier M. et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017; 136(21). https://doi.org/10.1161/CIRCULATIONAHA.117.030571
  • Drobni Z.D. et al. Association between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020; 142(24). https://doi.org/10.1161/CIRCULATIONAHA.120.049981
  • Salem J.E. et al. Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: A pharmacovigilance study. Lancet Oncol. 2018; 19(12). https://doi.org/10.1016/S1470-2045(18)30608-9
  • D’Souza M. et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2021; 42(16). https://doi.org/10.1093/eurheartj/ehaa884
  • Thuny F., Naidoo J., Neilan T.G. Cardiovascular complications of immune checkpoint inhibitors for cancer. European Heart Journal. 2022; 43(42). https://doi.org/10.1093/eurheartj/ehac456
  • Zhang L. et al. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer. JACC: CardioOncology. 2021; 3(1). https://doi.org/10.1016/j.jaccao.2020.11.012
  • Rubio-Infante N. et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021; 23(10). https://doi.org/10.1002/ejhf.2289

    • Загрузки

    Опубликован

    25-03-2024

    Как цитировать

    Зарханов Т. С., Ложкина Н. Г. ПОИСК МЕТАБОЛОМНЫХ ПРЕДИКТОРОВ СЕРДЕЧНО-СОСУДИСТЫХ ОСЛОЖНЕНИЙ У ПАЦИЕНТОВ С ВПЕРВЫЕ ВЫЯВЛЕННЫМ НЕМЕЛКОКЛЕТОЧНЫМ РАКОМ ЛЕГКОГО (ОБЗОР): УДК 616.24-006.6:616.1-071 // Бюллетень медицинской науки, 2024. Т. 33, № 1. С. 128–135 DOI: 10.31684/25418475-2024-1-128. URL: https://newbmn.asmu.ru/bmn/article/view/673.

    Выпуск

    Том 33 № 1 (2024): Бюллетень медицинской науки

    Раздел

    ОБЗОРЫ

    Лицензия

    Лицензия Creative Commons

    Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.

    Наиболее читаемые статьи этого автора (авторов)